A randomised controlled trial to evaluate the effect of maternal or neonatal pneumococcal conjugate vaccination on pneumococcal carriage in early life
一项随机对照试验,旨在评估孕产妇或新生儿肺炎球菌结合疫苗接种对生命早期肺炎球菌携带的影响
基本信息
- 批准号:MC_EX_MR/M007529/1
- 负责人:
- 金额:$ 180.51万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2014
- 资助国家:英国
- 起止时间:2014 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The last decade has witnessed significant reductions in the number of children dying before they reach their fifth birthday (under-five mortality) across the world. Despite this, we fall far short of Millennium Development Goal 4 which called for a two-third reduction in under-five mortality between 1990 and 2015. Overall, 70 percent of under-five mortality (5.4 million deaths, 2010) occurs in those under the age of one and forty percent occurs in the first month of life. Nearly half of all deaths occur in sub-Saharan Africa, with countries in West Africa, including The Gambia, having the highest mortality rates anywhere in the world. Consequently, new interventions to reduce mortality in early infancy in this setting have tremendous potential for life-saving impact. Streptococcus pneumoniae (or pneumococcus) is a leading cause of childhood mortality worldwide. Recent estimates suggest the bacteria are responsible for around 11 percent of deaths in children under five, with over half of these deaths occurring in Africa. Infants in this setting become rapidly 'colonised' with bacteria in the back of the nose. For example, in The Gambia, over 80 percent of infants will be carrying the bacteria by two months of age. Carriage is an immediate and necessary precursor to disease. Reflecting these high carriage rates, a recent systematic review confirmed that pneumococcus is the leading cause of life-threatening infections, both sepsis and meningitis, in infants up to three months of age in sub-Saharan Africa. The burden of pneumonia related mortality is similarly extremely high in the same group.The currently available pneumococcal-conjugate vaccines (PCV) are recommended by the WHO according to a three dose six, 10 and 14 week schedule. As a result, infants are not protected against pneumococcus until 16 to 18 weeks of age, or later if the vaccines are delayed, by which point a significant burden of pneumococcal related mortality has already occurred. Therefore, the objective of this trial is to explore alternative schedules for PCV administration to prevent pneumococcal disease in this critical window of susceptibility. Two intervention arms will be compared to a control arm in which infants will receive PCV according to a standard three dose schedule. In the maternal intervention arm, expectant mothers will be given a dose of PCV in the third trimester of pregnancy. This aims to boost the mother's pneumococcal antibody levels with the expectation that these will be transferred to the infant across the placenta and in breast milk, thus protecting the infant from birth. In the neonatal intervention arm, a dose of the vaccine will be administered to newborns on the first day of life with the aim of generating a protective immune response in the newborn as early as possible. The rate at which the infants acquire pneumococcal carriage in the back of the nose will be compared between the two intervention arms and the control arm. Given the link between carriage and disease, the rate of carriage acquisition is becoming an established 'surrogate' for disease in pneumococcal vaccine trials, substantially reducing the size and complexity of the trials required. Antibody levels and other measures of pneumococcal immunity will also be measured and important safety data will be collected throughout. Given the sensitivity of vaccination in both expectant mothers and newborns the trial will also examine the acceptability of these interventions with the aim of identifying any barriers to implementation. The WHO already recommends PCV vaccination and the vaccines are provided to eligible countries through funding provided by the GAVI Alliance. Consequently, a policy change influenced by the results of this trial could be rapidly implemented without major barriers. Given the burden of disease in infancy, if proven, the impact of the trial in terms of lives saved in early life could be rapidly significant.
在过去十年中,全世界儿童在五岁以下死亡(五岁以下儿童死亡率)的人数大幅减少。尽管如此,我们远远没有达到千年发展目标4,该目标要求在1990年至2015年期间将五岁以下儿童的死亡率降低三分之二。总体而言,70%的五岁以下儿童死亡率(2010年为540万例死亡)发生在一岁以下儿童中,40%发生在婴儿出生后的第一个月。近一半的死亡发生在撒哈拉以南非洲,包括冈比亚在内的西非国家的死亡率是世界上最高的。因此,在这种情况下,降低婴幼儿早期死亡率的新干预措施具有巨大的拯救生命的潜力。肺炎链球菌(或肺炎球菌)是全球儿童死亡的主要原因。最近的估计表明,这种细菌导致了大约11%的五岁以下儿童死亡,其中一半以上发生在非洲。在这种情况下,婴儿很快就会被鼻背上的细菌“殖民”。例如,在冈比亚,超过80%的婴儿在两个月大时将携带这种细菌。携带是疾病的直接和必要的先兆。最近的一项系统回顾证实,肺炎球菌是撒哈拉以南非洲三个月以下婴儿感染--包括败血症和脑膜炎--的主要原因,反映了这些高携带率。与肺炎相关的死亡率负担在同一组中同样极高。目前可用的肺炎球菌结合疫苗(PCV)是世界卫生组织推荐的,按6、10和14周三剂的时间表接种。因此,婴儿直到16到18周大时才能对肺炎球菌产生保护,或者如果疫苗延迟接种,婴儿就不会受到肺炎球菌的保护,到那时,与肺炎球菌相关的死亡已经出现了很大的负担。因此,这项试验的目的是探索PCV给药的替代方案,以在这一关键的易感窗口预防肺炎球菌病。两个干预组将与对照组进行比较,在对照组中,婴儿将按照标准的三剂表接受PCV。在孕产妇干预臂中,孕妇将在怀孕第三个月时获得一剂PCV。这旨在提高母亲的肺炎球菌抗体水平,期望这些抗体将通过胎盘和母乳传染给婴儿,从而保护婴儿免受出生的伤害。在新生儿干预组,将在新生儿出生的第一天接种一剂疫苗,目的是尽早在新生儿中产生保护性免疫反应。将比较两个干预组和控制组的婴儿鼻后部肺炎球菌携带率。鉴于携带者与疾病之间的联系,携带者的获得率正在成为肺炎球菌疫苗试验中疾病的既定“替代品”,大大降低了所需试验的规模和复杂性。还将测量抗体水平和肺炎球菌免疫的其他措施,并收集重要的安全数据。鉴于孕妇和新生儿接种疫苗的敏感性,试验还将审查这些干预措施的可接受性,目的是查明执行方面的任何障碍。世界卫生组织已经建议接种PCV疫苗,并通过GAVI联盟提供的资金向符合条件的国家提供疫苗。因此,受这一试验结果影响的政策变化可以在没有重大障碍的情况下迅速实施。考虑到婴儿期的疾病负担,如果得到证实,这项试验在挽救早期生命方面的影响可能很快就会显著。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Pneumococcal conjugate vaccination schedules in infants-acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study.
肺炎球菌偶联疫苗接种时间表在婴儿辅助,免疫原性和肺炎球菌缀合物和黄热病疫苗共同给药研究中。
- DOI:10.1186/s13063-021-05949-4
- 发表时间:2022-01-15
- 期刊:
- 影响因子:2.5
- 作者:Mackenzie GA;Osei I;Salaudeen R;Secka O;D'Alessandro U;Clarke E;Schmidt-Chanasit J;Licciardi PV;Nguyen C;Greenwood B;Mulholland K
- 通讯作者:Mulholland K
Viewpoint: vaccine inequity in the spotlight.
- DOI:10.1136/archdischild-2021-322940
- 发表时间:2022-12
- 期刊:
- 影响因子:5.2
- 作者:
- 通讯作者:
The Fourth International Neonatal and Maternal Immunization Symposium (INMIS 2017): Toward Integrating Maternal and Infant Immunization Programs.
第四届国际新生儿和母体免疫研讨会(INMIS 2017):旨在整合母亲和婴儿免疫计划。
- DOI:10.1128/msphere.00221-18
- 发表时间:2018-11-07
- 期刊:
- 影响因子:4.8
- 作者:Munoz FM;Van Damme P;Dinleyici E;Clarke E;Kampmann B;Heath PT;Levy O;Leuridan E;Cutland C;Sobanjo-Ter Meulen A;Marchant A
- 通讯作者:Marchant A
Prior upregulation of interferon pathways in the nasopharynx impacts viral shedding following live attenuated influenza vaccine challenge in children.
- DOI:10.1016/j.xcrm.2021.100465
- 发表时间:2021-12-21
- 期刊:
- 影响因子:0
- 作者:Costa-Martins AG;Mane K;Lindsey BB;Ogava RLT;Castro Í;Jagne YJ;Sallah HJ;Armitage EP;Jarju S;Ahadzie B;Ellis-Watson R;Tregoning JS;Bingle CD;Bogaert D;Clarke E;Ordovas-Montanes J;Jeffries D;Kampmann B;Nakaya HI;de Silva TI
- 通讯作者:de Silva TI
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ed Clarke其他文献
The waning of maternal measles antibodies: A multi-country maternal-infant seroprevalence study
母体麻疹抗体的减弱:一项多国母婴血清流行率研究
- DOI:
10.1016/j.jinf.2025.106531 - 发表时间:
2025-08-01 - 期刊:
- 影响因子:11.900
- 作者:
Karen S. Tiley;Hinke ten Hulscher-van Overbeek;Sudha Basnet;Rob van Binnendijk;Ed Clarke;Stephen Cose;Duc Anh Dang;Ha Thi Thu Hoang;Beth Holder;Olubukola T. Idoko;Beate Kampmann;Freddie Kibengo;Fiona van der Klis;Abdul Momin Kazi;Elke Leuridan;Kirsten Maertens;Herberth Maldonado;Mary Nyantaro;Saad Omer;Marcela F. Pasetti;Merryn Voysey - 通讯作者:
Merryn Voysey
The normal function of the immune system in a clinical context
- DOI:
10.1016/j.paed.2012.11.014 - 发表时间:
2013-03-01 - 期刊:
- 影响因子:
- 作者:
Ed Clarke - 通讯作者:
Ed Clarke
Circulation of respiratory viruses during the COVID-19 pandemic in The Gambia [version 2; peer review: 2 approved]
冈比亚 COVID-19 大流行期间呼吸道病毒的传播[第 2 版;
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
S. Jarju;Elina Senghore;H. Brotherton;Alasana Saidykhan;Samba Jallow;Ebrima Krubally;Edrisa Sinjanka;Morris Ngor Ndene;Fabakary Bajo;Musa M Sanyang;B. Saidy;Alasana Bah;Nuredin Mohammed;Karen Forrest;Ed Clarke;U. Dalessandro;A. Sesay;Effua Usuf;Carla Cerami;A. Roca;B. Kampmann;T. I. Silva;I. Asante;Antonia Ho - 通讯作者:
Antonia Ho
HPV vaccination acceptance and perceptions related to fertility and population control in the Gambia: An anthropological analysis
- DOI:
10.1016/j.vaccine.2023.04.072 - 发表时间:
2023-06-01 - 期刊:
- 影响因子:
- 作者:
Rose J. Wilson;Lamin Leigh;Haddy Bah;Heidi J. Larson;Ed Clarke - 通讯作者:
Ed Clarke
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial
2型新型口服脊髓灰质炎疫苗(nOPV2)在1至<5岁婴幼儿中的安全性以及冈比亚婴幼儿对nOPV2免疫反应的批次间一致性:一项3期双盲随机对照试验
- DOI:
10.1016/s0140-6736(23)02844-1 - 发表时间:
2024-03-23 - 期刊:
- 影响因子:88.500
- 作者:
Magnus Ochoge;Ahmed Cherno Futa;Ama Umesi;Lucy Affleck;Larry Kotei;Baboucarr Daffeh;Ebrima Saidy-Jah;Anna Njie;Oluwafemi Oyadiran;Bassey Edem;Musa Jallow;Edrissa Jallow;Simon A Donkor;Erman Tritama;Talha Abid;Kathryn A V Jones;Bernardo A Mainou;John O Konz;Alan Fix;Chris Gast;Ed Clarke - 通讯作者:
Ed Clarke
Ed Clarke的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ed Clarke', 18)}}的其他基金
HPV, STI and AMR in West Africa: estimating population burden and understanding exposures to accelerate vaccine impact and drive new interventions
西非的 HPV、STI 和 AMR:估计人口负担并了解暴露情况,以加速疫苗的影响并推动新的干预措施
- 批准号:
MR/W002116/1 - 财政年份:2022
- 资助金额:
$ 180.51万 - 项目类别:
Research Grant
ICF: Unmanned aerial vehicles ('drones') for sustainable vaccine research and improving equity in vaccine delivery: a feasibility study in The Gambia
ICF:用于可持续疫苗研究和提高疫苗交付公平性的无人机(“无人机”):冈比亚的可行性研究
- 批准号:
MR/X011771/1 - 财政年份:2022
- 资助金额:
$ 180.51万 - 项目类别:
Research Grant
A non-inferiority trial to assess the safety and immunogenicity of yellow fever vaccine dose sparing strategies for campaign and programmatic use
一项非劣效性试验,旨在评估用于运动和规划使用的黄热病疫苗剂量节约策略的安全性和免疫原性
- 批准号:
MC_EX_MR/R006148/1 - 财政年份:2017
- 资助金额:
$ 180.51万 - 项目类别:
Research Grant
A randomised, observer-blind, non-inferiority trial to evaluate alternative human papillomavirus vaccination schedules in young females in West Africa
一项随机、观察者盲法、非劣效性试验,旨在评估西非年轻女性的替代人乳头瘤病毒疫苗接种计划
- 批准号:
MC_EX_MR/N006070/1 - 财政年份:2015
- 资助金额:
$ 180.51万 - 项目类别:
Research Grant
相似国自然基金
槲皮素控释系统调控Mettl3/Per1修复氧化应激损伤促牙周炎骨再生及机制研究
- 批准号:82370921
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
肿瘤翻译调控蛋白调控大肠癌细胞转移能力的信号机制研究
- 批准号:81000952
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
多肽树状物为载体的抗癌前体药物的合成和研究
- 批准号:81072530
- 批准年份:2010
- 资助金额:36.0 万元
- 项目类别:面上项目
植物病毒壳体"智能"纳米载体靶向肿瘤细胞的研究
- 批准号:30973685
- 批准年份:2009
- 资助金额:35.0 万元
- 项目类别:面上项目
高臭氧浓度下水稻颖花和粒重形成受阻及其成因-FACE研究
- 批准号:30871486
- 批准年份:2008
- 资助金额:29.0 万元
- 项目类别:面上项目
相似海外基金
Memory Reshaping for Depression: A Remote Digital Randomised Controlled Feasibility Trial
抑郁症记忆重塑:远程数字随机控制可行性试验
- 批准号:
MR/Y008545/1 - 财政年份:2024
- 资助金额:
$ 180.51万 - 项目类别:
Research Grant
ExtraCECI: A cluster randomised controlled trial of community-based person-centred enhanced care for people with HIV/AIDS in Ghana
ExtraCECI:一项以社区为基础、以人为本的强化对加纳艾滋病毒/艾滋病患者护理的整群随机对照试验
- 批准号:
MR/Y019865/1 - 财政年份:2024
- 资助金额:
$ 180.51万 - 项目类别:
Research Grant
Randomized controlled trial of in-person and virtual Symptom screening with Targeted Early Palliative care (STEP2) in patients with advanced cancer
对晚期癌症患者进行有针对性的早期姑息治疗 (STEP2) 进行现场和虚拟症状筛查的随机对照试验
- 批准号:
490098 - 财政年份:2023
- 资助金额:
$ 180.51万 - 项目类别:
Operating Grants
Sedation Practice in Intensive Care Evaluation: Early Sedation with Dexmedetomidine in Older Ventilated Critically Ill Patients (SPICE-IV): A Randomised Double-Blind Placebo-Controlled Trial
重症监护评估中的镇静实践:老年通气危重患者早期使用右美托咪定镇静 (SPICE-IV):一项随机双盲安慰剂对照试验
- 批准号:
477888 - 财政年份:2023
- 资助金额:
$ 180.51万 - 项目类别:
Operating Grants
MICA: Can interferon gamma prevent infection in critically ill patients at highest risk? A phase II randomised controlled trial.
MICA:γ 干扰素能否预防高风险危重患者的感染?
- 批准号:
MR/X004929/1 - 财政年份:2022
- 资助金额:
$ 180.51万 - 项目类别:
Research Grant
Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine plus dihydroartemisinin-piperaquine to reduce adverse pregnancy outcomes and prevent malaria in Papua New Guinea: a randomised controlled trial
在巴布亚新几内亚,用磺胺多辛-乙胺嘧啶加双氢青蒿素-哌喹对妊娠期进行间歇性预防治疗,以减少不良妊娠结局并预防疟疾:一项随机对照试验
- 批准号:
nhmrc : 2000780 - 财政年份:2022
- 资助金额:
$ 180.51万 - 项目类别:
Clinical Trials and Cohort Studies Grants
Personalized integrated COgnitive-Sensory-MOtor training(iCOSMO) intervention to improve arm and hand function after chronic stroke: a pilot randomised controlled trial
个性化综合认知-感觉-运动训练(iCOSMO)干预以改善慢性中风后手臂和手部功能:一项试点随机对照试验
- 批准号:
460604 - 财政年份:2022
- 资助金额:
$ 180.51万 - 项目类别:
Parent-Delivered Early Language Intervention for Children with Down Syndrome: A Randomised Controlled Feasibility Trial
家长对唐氏综合症儿童进行早期语言干预:随机对照可行性试验
- 批准号:
ES/V016946/1 - 财政年份:2022
- 资助金额:
$ 180.51万 - 项目类别:
Research Grant
A novel placebo-based intervention for migraine: Randomised controlled trial
一种新颖的基于安慰剂的偏头痛干预措施:随机对照试验
- 批准号:
474000 - 财政年份:2022
- 资助金额:
$ 180.51万 - 项目类别:
Fellowship Programs
Minimising bone mineral density loss in traumatic amputees: a randomised controlled feasibility trial
最大限度地减少创伤性截肢者的骨矿物质密度损失:一项随机对照可行性试验
- 批准号:
EP/X027155/1 - 财政年份:2022
- 资助金额:
$ 180.51万 - 项目类别:
Fellowship